Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZR123 (CPI-0209) in Advanced Solid Tumors and Lymphomas
2023-508002-20-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2 trial of tulmimetostat in transitional cell carcinoma (TCC), clear cell ovarian cancer, endometrial cancer (EC) and 10 more (10 arms), sponsored by Novartis. Primary endpoints: Occurrence of dose-limiting toxicities during the first treatment cycle and Objective response rate (Phase 2 monotherapy). Planned start Apr 2024; status: authorised.
02
Drugs
tulmimetostat
03
Conditions
transitional cell carcinoma (TCC)clear cell ovarian cancerendometrial cancer (EC)peripheral T-cell lymphoma (PTCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2023-508002-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508002-20-00.